This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).
By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.
Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.
The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.